In a heated exchange on Tuesday, Andrew Left, a short seller and founder and executive editor of Citron Research, took on Mallinckrodt's CEO, Mark Trudeau, about the value of his pharmaceutical company and how it differs from Valeant.
Left, who called the decline in Valeant back in October, told CNBC's "Fast Money" on Tuesday that Mallinckrodt makes Valeant look like a "choirboy" by comparison.
Read Full Article »